William Blair & Company
TOVX icon

William Blair & Company’s Theriva Biologics TOVX Stock Holding History

William Blair & Company’s Portfolio TOVX Stock Details TOVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-406
Closed -$2.4K – 1874
2024
Q2 		$2.4K Hold
406
– – ﹤0.01% 1796
2024
Q1 		$4.76K Hold
406
– – ﹤0.01% 1749
2023
Q4 		$4.37K Buy
+406
New +$5K ﹤0.01% 1742
2022
Q4 		– Sell
-1,268
Closed -$31K – 1878
2022
Q3 		$31K Buy
1,268
+55
+5% +$2.11K ﹤0.01% 1653
2022
Q2 		$65K Buy
1,213
+183
+18% +$10.5K ﹤0.01% 1596
2022
Q1 		$73K Buy
1,030
+166
+19% +$11.3K ﹤0.01% 1663
2021
Q4 		$59K Buy
864
+49
+6% +$4.62K ﹤0.01% 1758
2021
Q3 		$94K Buy
815
+130
+19% +$16.2K ﹤0.01% 1619
2021
Q2 		$103K Buy
685
+402
+142% +$57.6K ﹤0.01% 1608
2021
Q1 		$48K Buy
283
+65
+30% +$12.8K ﹤0.01% 1673
2020
Q4 		$21K Buy
218
+7
+3% +$613 ﹤0.01% 1698
2020
Q3 		$25K Sell
211
-33
-14% -$4.4K ﹤0.01% 1566
2020
Q2 		$31K Buy
244
+26
+12% +$2.48K ﹤0.01% 1495
2020
Q1 		$18K Buy
218
+13
+6% +$1.48K ﹤0.01% 1505
2019
Q4 		$26K Sell
205
-7
-3% -$745 ﹤0.01% 1551
2019
Q3 		$24K Sell
212
-4
-2% -$483 ﹤0.01% 1526
2019
Q2 		$30K Sell
216
-10
-4% -$1.44K ﹤0.01% 1550
2019
Q1 		$38K Buy
226
+48
+27% +$7.95K ﹤0.01% 1502
2018
Q4 		$25K Buy
+178
New +$42.3K ﹤0.01% 1462
2018
Q3 		– Sell
-253
Closed -$529K – 1668
2018
Q2 		$529K Buy
253
+27
+12% +$62K ﹤0.01% 928
2018
Q1 		$631K Buy
226
+29
+15% +$110K ﹤0.01% 846
2017
Q4 		$877K Buy
+197
New +$1.23M 0.01% 778
2017
Q3 		– Sell
-183
Closed -$906K – 1505
2017
Q2 		$906K Sell
183
-4
-2% -$19.9K 0.01% 785
2017
Q1 		$1.29M Sell
187
-1
-0.5% -$6.98K 0.01% 640
2016
Q4 		$1.26M Sell
188
-40
-18% -$411K 0.01% 600
2016
Q3 		$3.44M Sell
228
-12
-5% -$180K 0.03% 378
2016
Q2 		$3.78M Sell
240
-57
-19% -$1.07M 0.04% 339
2016
Q1 		$6.13M Buy
297
+32
+12% +$481K 0.06% 262
2015
Q4 		$5.31M Buy
265
+59
+29% +$1.25M 0.05% 281
2015
Q3 		$4.1M Buy
206
+82
+66% +$2.02M 0.04% 358
2015
Q2 		$3.1M Buy
+124
New +$2.49M ﹤0.01% 1199

Other funds holding TOVX

HCM
Heights Capital Management San Francisco, California $359M AUM 7.93% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

William Blair & Company's TOVX Position: Q3 2024 in Review

William Blair & Company sold out of Theriva Biologics (TOVX) in Q3 2024, closing a stake of 406 shares — an estimated $2.4K sold.

William Blair & Company first reported a position in TOVX in Q2 2015 and held it in 31 quarters. The position peaked at $6.13M in Q1 2016. 18 funds tracked by Wall St. Rank hold TOVX as of Q3 2024.

  • William Blair & Company reported no remaining Theriva Biologics position as of Q3 2024 after selling out during the quarter.
  • William Blair & Company sold 406 Theriva Biologics shares in Q3 2024, an estimated $2.4K.
  • William Blair & Company first reported a position in Theriva Biologics in Q2 2015 and held it in 31 quarters.
  • William Blair & Company's Theriva Biologics position peaked at $6.13M in Q1 2016.
  • 18 funds tracked by Wall St. Rank held Theriva Biologics as of Q3 2024.

Based on William Blair & Company's 13F filing for Q3 2024, filed 12 Nov 2024.